Pembrolizumab biosimilar is under clinical development by Biocad and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pembrolizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pembrolizumab biosimilar overview
Pembrolizumab (Pembroria) is an antineoplastic immunomodulating agent. Pembroria is formulated as concentrate solution for intravenous route of administration. Pembroria is indicated for the treatment of anaplastic large cell lymphoma, cervical cancer,endometrial cancer,esophageal cancer, head and neck squamous cell carcinoma, hodgkin lymphoma (b-cell hodgkin lymphoma), malignant neoplasms, metastatic colorectal cancer, metastatic melanoma, metastatic transitional (urothelial) tract cancer, non muscle invasive bladder cancer (nmibc) (superficial bladder cancer), non-small cell lung cancer, renal cell carcinoma, squamous non-small cell lung cancer, triple-negative breast cancer.
Pembrolizumab biosimilar is under development for the treatment of solid tumors, metastatic melanoma and non-small cell lung cancer. It acts by targeting programmed cell death protein 1 (PD1). It is administered through intravenous route.
Biocad overview
JSC Biocad (Biocad) is a biotechnology company that conducts research and development services. The company develops, manufactures, and distributes generic pharmaceutical products. Its products portfolio comprise rituximab, bevacizumab, trastuzumab, prolgolimab, levilimab, netakimab and eculizumab. Biocad develops products in the form of suppositories, spray, and drops. The compay provides products under the brands Avegra, Herticad, Gerticad, Forteka, Extimia and Leucostim. It manufactures products in the therapeutic areas such as oncology, rare disease, autoimmune diseases, and infectious diseases. The company’s R&D centers are located in Lyubuchany, Neudorf and Frontovaya. It operates in Brazil, China, Russia, the UAE and Vietnam. Biocad is headquartered in Saint-Petersburg, Russia.
For a complete picture of Pembrolizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
